FGF-13 Activators
FGF-13 activators are a diverse class of small molecule chemicals that enhance the functional activity of Fibroblast Growth Factor-13 (FGF-13), a protein implicated in intracellular signaling and the regulation of neuronal ion channels. These activators do not directly bind to FGF-13; instead, they modulate various cellular signaling pathways that indirectly augment the role of FGF-13 in neuronal function and maintenance. For instance, compounds like forskolin elevate intracellular levels of cyclic adenosine monophosphate (cAMP) by activating adenylate cyclase. The subsequent increase in cAMP enhances the activity of protein kinase A (PKA), a kinase that can phosphorylate a broad spectrum of target proteins involved in neuronal signaling. The phosphorylation events mediated by PKA have the potential to increase the functional activity of FGF-13, particularly by promoting its association with sodium channels, thereby modulating neuronal excitability.
Moreover, other members of the FGF-13 activator class, such as dibutyryl-cAMP, act as analogs of cAMP and can directly activate PKA, leading to similar outcomes as forskolin. Vinpocetine and rolipram, by inhibiting phosphodiesterase enzymes, increase cAMP levels, further contributing to the PKA-mediated phosphorylation cascade. Additionally, pregnenolone sulfate, a neurosteroid, enhances synaptic transmission through its modulation of NMDA receptor activity, which can lead to the activation of calcium-dependent signaling pathways. These pathways are essential for the regulation of neuronal growth and differentiation, where FGF-13 is an important modulator. Furthermore, compounds like tetrodotoxin and ZD7288, by modulating the activity of sodium channels and HCN channels, respectively, indirectly influence the functional activity of FGF-13. They do so by eliciting compensatory cellular responses that can lead to the upregulation of FGF-13 or by altering the excitability of neurons, thus affecting the dynamics of neuronal signaling in which FGF-13 is involved.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
An adenylate cyclase activator that increases intracellular cAMP levels, enhancing PKA activity and phosphorylation of target proteins. This may indirectly increase the functional activity of FGF-13 by promoting its association with regulated sodium channels. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
A vitamin A metabolite that acts as a transcriptional regulator, which may upregulate genes involved in neuronal differentiation processes where FGF-13 is implicated, thus potentially enhancing its activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A membrane-permeable cAMP analog that activates PKA and may enhance the phosphorylation of proteins that regulate neuronal excitability, including those associated with FGF-13. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
An activator of PKC which can alter the phosphorylation state of sodium channels that FGF-13 regulates, potentially affecting its regulatory role. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
A protein synthesis inhibitor that activates stress-activated protein kinases, which could alter neuron function and plasticity where FGF-13 plays a part. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
A PDE4 inhibitor that increases cAMP levels, leading to increased PKA activity and potentially enhancing the role of FGF-13 in modulating neuronal ion channels. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
A PDE1 inhibitor that may enhance PKA and PKG activity, potentially augmenting the modulation of ion channels and synaptic plasticity by FGF-13. | ||||||